Comparative Pharmacology
Head-to-head clinical analysis: AMPHOTEC versus TIOCONAZOLE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMPHOTEC versus TIOCONAZOLE.
AMPHOTEC vs TIOCONAZOLE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amphotericin B binds to ergosterol in fungal cell membranes, forming pores that disrupt membrane integrity, leading to leakage of intracellular contents and cell death.
Inhibition of fungal CYP450-dependent 14α-demethylase, blocking ergosterol synthesis and disrupting fungal cell membrane integrity.
Initial dose: 0.5 mg/kg intravenously once daily, titrated as tolerated to 5 mg/kg once daily.
Topical: Apply 1% cream, lotion, or solution to affected area twice daily for 2-4 weeks. Vaginal: Insert 1 applicatorful of 6.5% ointment intravaginally at bedtime as a single dose.
None Documented
None Documented
Terminal half-life: 24-48 hours (up to 7 days in hepatic impairment). Long half-life allows once-daily dosing.
Clinical Note
moderateTioconazole + Tranilast
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tranilast."
Clinical Note
moderateTioconazole + Tolfenamic acid
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Tolfenamic acid."
Clinical Note
moderateTioconazole + Nimesulide
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Nimesulide."
Clinical Note
moderateTioconazole + Risedronic acid
Terminal elimination half-life is approximately 24–30 hours after topical application, reflecting slow systemic clearance of absorbed fraction.
Biliary/fecal: ~90% unchanged; renal: <10% (mainly as metabolite).
Primarily fecal (minimally absorbed; <5% absorbed dose excreted renally as metabolites); topically applied tioconazole is largely unabsorbed.
Category C
Category A/B
Antifungal
Antifungal
"The risk or severity of adverse effects can be increased when Tioconazole is combined with Risedronic acid."